Search research articles
Contact Us
Filters
Showing results (21-30 of 104) with videos related to
Page
of 11
Sort By:
Psychopharmacology
|
March 14, 2012
Comment on: "Effects of a novel mGlu(2/3) receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid" (Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K, Psychopharmacology, 2012)
Philip Seeman
Journal of Clinical Psychopharmacology
|
March 6, 2012
Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al
Philip Seeman
International Journal of Geriatric Psychiatry
|
September 27, 2014
Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer's disease
Philip Seeman
Neuropharmacology
|
August 14, 2012
An agonist at glutamate and dopamine D2 receptors, LY404039
Philip Seeman
CNS Neuroscience & Therapeutics
|
March 16, 2011
Schizophrenia diagnosis and treatment
Philip Seeman
Journal of Psychiatry & Neuroscience : JPN
|
March 10, 2009
Glutamate and dopamine components in schizophrenia
Philip Seeman
Schizophrenia Research
|
January 28, 2009
Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High)
Philip Seeman
Synapse (New York, N.Y.)
|
February 4, 2015
Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors
Philip Seeman
Synapse (New York, N.Y.)
|
July 23, 2003
Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors
Philip Seeman, Shitij Kapur
Synapse (New York, N.Y.)
|
June 3, 2011
Alzheimer's disease: β-amyloid plaque formation in human brain
Philip Seeman, Neil Seeman
Page
of 11
Search research articles
Search
Showing results (21-30 of 104) with videos related to
Sort By:
Page
of 11
Psychopharmacology
|
March 14, 2012
Comment on: "Effects of a novel mGlu(2/3) receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid" (Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K, Psychopharmacology, 2012)
Philip Seeman
Journal of Clinical Psychopharmacology
|
March 6, 2012
Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al
Philip Seeman
International Journal of Geriatric Psychiatry
|
September 27, 2014
Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer's disease
Philip Seeman
Neuropharmacology
|
August 14, 2012
An agonist at glutamate and dopamine D2 receptors, LY404039
Philip Seeman
CNS Neuroscience & Therapeutics
|
March 16, 2011
Schizophrenia diagnosis and treatment
Philip Seeman
Journal of Psychiatry & Neuroscience : JPN
|
March 10, 2009
Glutamate and dopamine components in schizophrenia
Philip Seeman
Schizophrenia Research
|
January 28, 2009
Schizophrenia model of elevated D2(High) receptors: haloperidol reverses the amphetamine-induced elevation in dopamine D2(High)
Philip Seeman
Synapse (New York, N.Y.)
|
February 4, 2015
Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors
Philip Seeman
Synapse (New York, N.Y.)
|
July 23, 2003
Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors
Philip Seeman, Shitij Kapur
Synapse (New York, N.Y.)
|
June 3, 2011
Alzheimer's disease: β-amyloid plaque formation in human brain
Philip Seeman, Neil Seeman
Page
of 11